A phase II study of M6620 in combination with carboplatin compared with docetaxel in combination with carboplatin in metastatic castration-resistant prostate cancer.

Atish D. Choudhury,Wanling Xie,Mamta Parikh,Daniel Lee,Elizabeth R. Kessler,David J. Einstein,Bose Kochupurakkal,Kent W. Mouw,Eliezer M. Van Allen,L. Austin Doyle,Alan D. D'Andrea,Mary-Ellen Taplin,Geoffrey I. Shapiro

A phase II study of M6620 in combination with carboplatin compared with docetaxel in combination with carboplatin in metastatic castration-resistant prostate cancer.

2020

Atish D. Choudhury
Wanling Xie
Mamta Parikh
Daniel Lee
Elizabeth R. Kessler
David J. Einstein
Bose Kochupurakkal
Kent W. Mouw
Eliezer M. Van Allen
L. Austin Doyle
Alan D. D'Andrea
Mary-Ellen Taplin
Geoffrey I. Shapiro

TPS252Background: Alterations in DNA damage repair genes are common in metastatic castration-resistant prostate cancer (mCRPC), and are implicated in responses to carboplatin, PARP inhibitors and i...

Keywords:

Pathology
Castration
Prostate cancer
Oncology
Internal medicine
Docetaxel
Medicine
Phases of clinical research
Carboplatin
castration resistant
DNA Damage Repair
Poly ADP ribose polymerase
Cancer research

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations